Во время пандемии COVID-19 произошло увеличение данных о здоровье (правильных и неправильных). Многие перешли на использование витаминов и добавок для борьбы с вирусом. В этой статье мы анализируем клинические испытания витаминов и добавок для лечения и профилактики инфекций COVID-19.
| № | Муаллифнинг исми | Лавозими | Ташкилот номи |
|---|---|---|---|
| 1 | Ergasheva Z.A. | autor | ASMI |
| № | Ҳавола номи |
|---|---|
| 1 | Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–644. doi: 10.1001/jama.2021.0202. |
| 2 | Kim YJ, Jang US, Soh SM, Lee JY, Lee HR. The impact on infectivity and neutralization efficiency of SARS-CoV-2 lineage B.1.351 Pseudovirus. Viruses. 2021;13(4):633. doi: 10.3390/v13040633. |
| 3 | Anti-SARS-CoV-2 Monoclonal Antibodies. National Institutes of Health, US Department of Health and Human Services; www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies. |
| 4 | Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19. US Food and Drug Administration; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19. |
| 5 | Pharmacologic Interventions. National Institutes of Health, US Department of Health and Human Services; www.covid19treatmentguidelines.nih.gov/critical-care/pharmacologic-interventions/ |